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Understanding the cellular pathways that regulate endothelial nitric oxide (eNOS,
NOS3) expression and consequently nitric oxide (NO) bioavailability during hypoxia is
a necessary aspect in the development of novel treatments for cardiovascular
disorders. eNOS expression and eNOS-dependent NO cellular signaling during
hypoxia promote an equilibrium of transcriptional and posttranscriptional molecular
mechanisms that belong to both proapoptotic and survival pathways. Furthermore,
NO bioavailability results not only from eNOS levels, but also relies on the presence
of eNOS substrate and cofactors, the phosphorylation status of eNOS, and the
presence of reactive oxygen species (ROS) that can inactivate eNOS. Since both NOS3
levels and these signaling pathways can also be a subject of posttranscriptional
modulation by microRNAs (miRNAs), this class of short noncoding RNAs contribute
another level of regulation for NO bioavailability. As miRNA antagomirs or specific
target protectors could be used in therapeutic approaches to regulate NO levels,
either by changing NOS3 mRNA stability or through factors governing eNOS activity,
it is critical to understand their role in governing eNOS activity during hypoxa. In
contrast to a large number of miRNAs reported to the change eNOS expression
during hypoxia, only a few miRNAs modulate eNOS activity. Furthermore, impaired
miRNA biogenesis leads to NOS3 mRNA stabilization under hypoxia. Here we discuss
the recent studies that define miRNAs’ role in maintaining endothelial NO
bioavailability emphasizing those miRNAs that directly modulate NOS3 expression or
eNOS activity.
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The signaling molecule nitric oxide (NO) produced in endothelium by nitric oxide
synthase 3 (eNOS, encoded by NOS3 gene) plays a pivotal role in the maintenance of
homeostasis in the blood vessel wall [1–3]. eNOS produces nitric oxide through
conversion of L-arginine and oxygen into L-citrulline and NO [4]. Rapid NO diffusion
to vascular smooth muscle cells leads to guanosine 3,5-cyclic monophosphate forma-
tion and consequently vasodilation [4]. Hence, impaired activity of eNOS and the loss
of NO bioavailability are associated with endothelial cell dysfunction that is an
independent risk factor for cardiovascular diseases [1, 2]. Endothelium dysfunction due
to the reduction of NO bioavailability in the vessel wall is one of the earliest manifesta-
tions of atherosclerosis and hypertension [5]. Although eNOS targeting is an attractive
approach in terms of preventing and treating atherosclerosis and other cardiovascular
disorders, the phenomenon of eNOS uncoupling hampers the attempts to assess
whether eNOS-derived NO serves to protect vessels from the progression of athero-
sclerosis. eNOS must be regarded as both an NO and an O2
--producing enzyme, and
therefore, eNOS may have dual effect on vascular function, depending on its functional
state [6–11]. Hence, future therapeutic approaches should rely on the physiologically
relevant restoration of endothelial NO homeostasis via modulation of eNOS activity
rather than just overexpression of this enzyme.
In endothelial cells, NOS3 is constitutively expressed. NOS3 message, however, is
strongly susceptible to upregulation by many factors including: ROS [12]; laminar and
oscillatory shear stress [13, 14], and cell growth [15]. The eNOS activity is regulated via
two mechanisms, calcium/calmodulin binding or phosphorylation by serine/threonine-
specific kinase (Akt) [16]. However, different physiological and pathological conditions
have been shown to affect NOS3 expression via both the transcriptional [17–19] and
post-transcriptional mechanisms [20–23]. Significantly, hypoxia/ischemia is a major
cellular stress that has a profound impact on endothelial cell biology, including cardio-
vascular pathologies. Thus, understanding the molecular mechanisms regulating NOS3
gene expression under low oxygen tension is a high-impact priority. Importantly,
prolonged hypoxia and ischemia lower endothelial NOS3 expression, leading to a loss
of NO bioavailability [23, 24]. In these instances, a major contributing factor to down-
regulation of NOS3 expression appears to be a reduction in the stability of NOS3
mRNA. This decrease in NOS3 mRNA abundance is attributed, at least in part, to the
destabilization of NOS3 mRNAs by a natural overlapping antisense transcript to NOS3
called sONE [23]. However during hypoxia, specific miRNAs may reduce endothelial
NOS3 levels and consequently modulate the bioavailability of NO [25]. Furthermore,
hypoxia often disturbs endoplasmic reticulum (ER) homeostasis, leading to ER stress
response activation [26]. Hence, besides hypoxia-related transcription factors and miR-
NAs, the transcriptional and post-transcriptional mediators (miRNAs) of the ER stress
pathway might also influence endothelial NO bioavailability.
Cardiovascular disorders and NO bioavailability
The endothelium plays a crucial role in regulating vascular function. Although serving
as an extremely active endocrine and paracrine organ that produces a large variety of
molecules participating in complex biochemical processes, the simple product gener-
ated by eNOS - NO - seems to be a key molecule required for the maintenance of
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tion. Thus, NOS3 knockout mice are hypertensive [27], whereas NOS3 transgenic mice
exhibit hypotension [28]. In addition, NO reduces the activation and aggregation of
platelets, attenuates adhesion of leukocytes to the endothelium, reduces the permeabil-
ity of the endothelium, and inhibits proliferation and migration of vascular smooth
muscle cells [29, 30]. Impaired activity of eNOS and the loss of NO bioavailability are
associated with endothelial cell dysfunction that is an independent risk factor for
cardiovascular diseases [1, 2]. A number of models of endothelial dysfunction in experi-
mental animals together with clinical data provided evidence that NO bioavailability is
reduced by increased production of reactive oxygen species (ROS) in the vessel wall. Of
ROS, superoxide (O2
–) is the key molecule as many other ROS are formed secondary
to the reactions involving O2
–. Because O2
– and NO are both radicals and contain
unpaired electrons in their outer orbitals, they undergo an extremely rapid, diffusion
limited radical-radical reaction, leading to the formation of peroxynitrite (ONOO–), a
much stronger oxidant than O2
– itself. There is growing evidence that an imbalance
between production NO and O2
- within the endothelium can contribute to the onset of
a variety of cardiovascular disease states such as atherosclerosis, thrombosis, hyperten-
sion, diabetes mellitus, heart failure, post-angioplasty restenosis, cerebral vasospasm
and delayed wound healing [1, 2, 7, 8]. Many of these disorders are associated with
hypoxia or ischemia in different organs and this leads to a decrease in oxygen and
nutrient delivery to the tissues. Importantly, hypoxia and ischemia lower endothelial
NOS3 expression, leading to loss of NO bioavailability.
eNOS uncoupling
Because O2
- avidly scavenges NO, a reduction of bioactive NO may occur despite an
increased NO generation. Among several enzymatic systems that are capable of produ-
cing O2
-, eNOS itself is a significant source of O2
- in the vessel wall [1, 7, 9, 10, 31]. In
the absence of a substrate, L-arginine, or a cofactor such as tetrahydrobiopterin (BH4),
eNOS synthesizes O2
- in preference to NO. In the process of eNOS dysfunction called
enzyme “uncoupling”, the electron flow through the eNOS enzyme is then diverted to
molecular oxygen rather than to L-arginine, which facilitates the production of O2
- ra-
ther than NO [7–9, 11]. Furthermore, during pathological conditions, eNOS mediates
formation of peroxynitrite (ONOO-) [32–34]. Hence, the extent of eNOS uncoupling is
dependent on ONOO- produced initially in the reaction between NO produced by
eNOS and O2
- generated by both NAD(P)H oxidase and eNOS [35, 36]. It has also
been suggested that both the zinc-thiolate center of eNOS and BH4 are probable targets
of oxidation by ONOO- [37]. This in turn can lead to dissociation of eNOS dimers to
monomers with the subsequent release of zinc cations [38]. Furthermore, cellular
studies have shown that phosphorylation of eNOS at specific amino acids (Ser-1177,
Thr-495) can regulate enzyme-mediated production of both NO and O2
- [39]. eNOS
uncoupling partially occurs even in normal endothelium and may explain the predis-
position of some individuals to endothelial dysfunction and cardiovascular complica-
tions. Although eNOS targeting is an attractive approach in terms of preventing and
treating atherosclerosis and other cardiovascular disorders, the phenomenon of eNOS
uncoupling hampers the attempts to assess whether eNOS-derived NO serves to pro-
tect vessels from the progression of atherosclerosis. eNOS must be regarded as both an
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vascular function, depending on its functional state [6–11].
Regulation of eNOS expression during hypoxia
The molecular basis of hypoxic vasodilation is not fully understood [40] and the
various effects of hypoxia on eNOS in endothelial cells have been described previously
[24]. Under normoxia, the NOS3 mRNA is highly stable in human endothelium [41].
However, eNOS activity and NOS3 expression levels are increased by hypoxia in some
reports [42–46], whereas in others they either decreased or not affected [24, 47, 48].
The discrepancies between these reports result from the duration of exposure to
hypoxia as well as from the different endothelial models used. Importantly, the pro-
longed hypoxia usually causes a decrease in NOS3 expression, while short-term oxygen
depletion leads to NOS3 mRNA accumulation in HUVECs (Fig. 1). The early hypoxic
induction of NOS3 expression was shown to rely on hypoxia-responsive elements
(HRE) at position _5375 to _5366 (relative to the transcription start site) [19]. NOS3
luciferase reporter studies illustrated that both of these HREs were functional for NOS3
promoter activity induction by hypoxia and by HIF-2 overexpression [19]. Hence,
during early hypoxia, HIFs and especially HIF-2 have been shown to induce NOS3
expression. Indeed, we previously demonstrated that HIF-1 is induced and accumulates
at the early stages of hypoxia in primary endothelial cells and this positively correlatesFig. 1 Hypoxia induces dynamic changes in the mRNA expression profiles of the NOS3, HIF1A and HIF2A
(EPAS1) in human human umbilical vein endothelial cells (HUVECs). The mRNA levels during hypoxia were
monitored in qRT-PCR experiments as described in [49, 50]. The results from 2 independent experiments
(n = 8) are plotted normalized to 18S rRNA levels and expressed as a fold-change compared to the normoxic
control. The hypoxia had no impact on HUVECs viability as monitored with Real Time xCelligence as described
in [106]. Error bars represent standard deviations. Significant changes (p < 0.05) are marked with an “*”
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creases at later stages of hypoxia [50] correlated with NOS3 mRNA levels, presumably
stabilizing NOS3 mRNA. Thus, further studies are required in order to better under-
stand the role HIFs in NOS3 expression modulation in response to hypoxia.
Under prolonged hypoxia, the reduction in stability of the mature NOS3 mRNA is a
major contributing factor to down-regulation of NOS3 expression [25]. Notably,
numerous studies have shown that hypoxia significantly down-regulates NOS3 mRNA
expression in endothelial cells [23, 24]. Furthermore, experimental models of prolifera-
tion/injury [51], tumor necrosis factor alpha treatment [52], and exposure to lipopoly-
saccharide [53] all decrease NOS3 steady-state mRNA expression in endothelial cells.
To date, numerous mechanisms responsible for NOS3 mRNA hypoxic reduction have
been proposed. The initial studies postulated that NOS3 mRNA destabilization during
hypoxia is inhibited by a Rho kinase inhibitor [54]. We have provided clear evidence
that Rho GTPase proteins negatively regulates eNOS expression and HMG-CoA reduc-
tase inhibitors (statins) upregulate eNOS expression by blocking Rho geranylgeranyla-
tion, which is necessary for its membrane-associated activity [55, 56]. However, recent
studies attributed the hypoxic decrease in NOS3 mRNA abundance, at least in part, to
the destabilization of NOS3 mRNAs by sONE (also known as ATG9B, NOS3AS, and
APG9L2) [57]. The NOS3 and sONE genes are arranged in a tail-to-tail orientation on
human chromosome 7q36, and the transcripts for the two genes are complementary
for a total of 662 nucleotides (including exon/exon overlap). During normoxia, the
sONE transcript is expressed at very low levels in endothelial cells, whereas NOS3 is
highly abundant [25]. Importantly, long-term hypoxia, which downregulates NOS3
mRNA and protein expression, significantly upregulates steady-state levels of sONE
RNA [23]. Importantly, basal expression of NOS3 mRNA is stabilized by the formation
of ribonucleoprotein RNP complexes on 3′-UTR cis elements. Recent studies identified
heterogenous nuclear RNP (hnRNP) E1, a ubiquitous, multifunctional RNA-binding
protein [25], as a major component of these eNOS-stabilizing RNP complexes [25].
Significantly, the stabilization of NOS3 mRNA by hnRNP E1 complexes constitutes a
protective mechanism against the posttranscriptional inhibitory effects of the NOS3
antisense transcript sONE and miRNAs (miR-765) during normoxic conditions [25]. In
normoxia, the hnRNP E1 complexes at NOS3 3′-UTR prevent sONE and miRNA bind-
ing. However, hypoxia disrupts hnRNP E1/NOS3 3′-UTR interactions via increased
Akt-mediated serine phosphorylation and nuclear localization of hnRNP E1, while
hnRNP E1 levels remain constant [25]. Hence, under hypoxic conditions, removal of
hnRNP-mediated protection of NOS3 mRNA makes this transcript susceptible to sONE
and miRNAs-related down-regulation.
All of the studies discussed above imply that hypoxic NOS3 mRNA levels are at equilib-
rium that result from the simultaneous interplay between HIF transcriptional induction of
NOS3 promoter and destabilization of NOS3 mRNA. Furthermore, the factors that modu-
late HIF signaling or sONE levels, such as miRNAs, could consequently influence NOS3
mRNA expression, and subsequently eNOS protein levels, and thus NO bioavailability.
Hypoxia-related ER stress activation
Recent studies also provided compiling evidence that disturbed ER function plays a crucial
role in a number of hypoxia-triggered endothelial patholophysiological processes leading
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vascular diseases, and neovascularization [58–60]. Hypoxia triggers endothelial ER
stress and apoptosis, and induces very low density lipoprotein (VLDL) receptor
(VLDLr) expression through HIF-1 transcriptional activity [61]. Since eNOS protein
biogenesis occurs in the ER, hypoxia-related ER stress activation could also modu-
late NOS3 expression at both the transcriptional and posttranscriptional levels [62].
Importantly, chemical ER stress induction was shown to decrease NOS3 mRNA
(Fig. 2) via a negative transcriptional effect on the proapoptotic transcription factor
C/EBP homologous protein (CHOP, also known as growth arrest and DNA damage
gene 153) [63]. CHOP is expressed at low levels during physiological conditions,
but is dramatically up-regulated in response to ER stress [64]. CHOP is a major
mediator of apoptosis, and has recently been shown to regulate angiogenesis [65].
During the early adaptive stages of ER stress, we observed NOS3 mRNA induction
(Fig. 2), suggesting the involvement of another mechanism. In line with this, it was
reported that overexpression of active form of proadaptive ER stress transcription
factor (XBP1s) upregulates both NOS3 mRNA and protein levels and leads to an increase
in NO production [66]. Overexpression of XBP1s increases Akt phosphorylation [67],
whereas the phosphorylation of NOS3 by Akt represents a major Ca2+-independent
regulatory mechanism for the activation of eNOS [68].
Hence, the hypoxic activation of ER stress additionally complicates the mechanism
for maintaining NOS3 mRNA levels and contributes at least two other importantFig. 2 The ER stress induced dynamic changes in the mRNA of the NOS3 that are negatively correlated
with CHOP expression in human umbilical vein endothelial cells (HUVECs). The ER stress was induced with
100 μM Calpain Inhibitor I (ALLN). mRNA levels were monitored in qRT-PCR experiments as described in
[106, 107]. The results from 2 independent experiments (n = 8) are plotted normalized to TBP mRNA levels
and expressed as a fold-change over the untreated control. Error bars represent standard deviations.
Significant changes (p < 0.05) are marked with an “*”
Kalinowski et al. Cellular & Molecular Biology Letters  (2016) 21:16 Page 7 of 15transcription factors oppositely modulating NOS3 mRNA abundance - survival XBP1
and proapoptotic CHOP.microRNAs - Regulation of NO production
miRNAs are short, single-stranded RNA molecules approximately 22 nucleotides in
length that that play key roles in the posttranscriptional regulation of gene expression.
As a component of miRNA-induced silencing complex (RISC), miRNAs initiate mRNA
decay and thus reduce protein output. The base-pairing interactions between nucleo-
tides 2 and 8 of the miRNA (the seed region) and complementary nucleotides in the
3′-untranslated region (3′-UTR) of mRNA are responsible for the miRNA specificity
[69]. Recent studies, however, indicate that miRNAs may play critical roles during
hypoxia [70] and ER stress [71].
Despite the fact that inhibiting miRNAs function (through DICER silencing [25])
prevents NOS3 down-regulation during hypoxia, only four miRNAs that directly affect
NOS3 expression have been identified that include miR-214 [72], miR-155 [73], miR-24
[74] and miR-765 [25].
miR-214 was reported to be induced in myocardial hypoxia as a indirect result of
HIF-1 activity [75]. In Human Umbilical Vein Endothelial Cells (HUVECs), downregu-
lation of miR-214 resulted in increased NOS3 expression (in normoxia) and miRNA
binding at NOS3 3′UTR was verified [75]. Hence, the hypoxic induction of miR-214
could be another factor destabilizing NOS3 message.
Direct binding of miR-24 to NOS3 mRNA was confirmed in HUVECs and resulted in
lowering eNOS protein levels in normoxia [74]. Although independent studies reported
miR-24 induction during hypoxia in human neuroblastoma cells [76], the expression
profile of this miRNA during hypoxia in human endothelium requires further study.
Recently, it was also proposed that XBP1-related down-regulation of some miRNAs
including miR-24, miR-125 and miR-214 may lead to NOS3 mRNA stabilization [66].
However, the role of ER stress and especially ER stress-specific miRNAs in modulating
NOS3 mRNA levels requires further study.
miR-155, that is induced during hypoxia in intestinal epithelial cells [77], was
also reported to directly bind to NOS3 3′UTR and reduce eNOS levels in human
endothelium [73]. miR-765, which is an abundant species (within the top 20 % of
all detected microRNAs) in HUVEC [78], binds to NOS3 mRNA at 3′ UTR region
that is stabilized in normoxia by hnRNP [25]. During hypoxia, however, hnRNP
dissociates from NOS3 mRNA sensitizing this transcript to miR-765-dependent
degradation [25].
miR-155, miR-214, and miR-24 were reported to destabilize NOS3 mRNA in
normoxia via the hnRNP-independent pathway. Therefore changes in these miRNAs
expression profiles modulate NOS3 mRNA levels during hypoxia. On the other hand,
miR-765 has no effect on NOS3 message in normoxia, while the effects of miR-765 on
NOS3 mRNA stability are hnRNP-dependent during hypoxia. Hence, we have example
of different mechanisms of miRNA-dependent NOS3 mRNA regulation during hypoxia.
The hnRNP-independent pathway allows dynamic and bidirectional modulation of
NOS3 mRNA stability up on induction or repression of miRNAs expression during
hypoxia. The hnRNP- dependent pathway (also utilized by sONE) allows rather
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require respectful change in miRNAs levels (especially if such a microRNAs are
abundant).
Importantly HIF-1, the main transcriptional mediator of cellular responses to hyp-
oxia, promotes the expression of several hypoxamiRs including miR-155 in intestinal
epithelial cells [77]. Furthermore, miR-155 has been shown to negatively regulate
HIF1A message levels, establishing a negative regulatory feedback loop during hypoxia
[77]. Interestingly, the cytokine TNF-α, known to dramatically destabilize NOS3 mRNA
[79], is also responsible for induction of miR-155 [80]. Thus, miR-155 provides a
sensitive link between transcriptional and posttranscriptional mechanisms that
regulate NOS3 expression during hypoxia through its actions on HIF-1A and NOS3
mRNA levels.
HIF-1 and HIF-2, therefore, are the perfect candidates for controlling NOS3 expres-
sion and NOS3-related cellular signaling during hypoxia. Interestingly, no miRNA has
been shown to control sONE nor HIF-2A levels in human endothelium.
Recently, the hypoxamiR miR-101 was shown to indirectly enhance the interaction
between HIF-1α and Hsp90 that resulted in both increased VEGF expression and
eNOS activity [81]. Both HIF-1 and HIF-2 induce proangiogenic vascular endothelial
growth factor (VEGF) expression [82]. VEGF subsequently leads to activation of Akt
and thus increased NO levels [83, 84]. Furthermore, hypoxia upregulates heat shock
protein 90 (Hsp90) expression in endothelial cells [85].. Hsp90 binds to the α subunits
of HIF-1, protecting this protein from oxygen-independent degradation and sustaining
HIF-1 transcriptional activity [86]. Importantly Hsp90 also increases eNOS activity
since it is required for the interaction of eNOS with Akt [87], and Hsp90 binding to
eNOS leads to increased affinity for calmodulin binding as well [88].
The other hypoxamiRs that modulate Akt phosphorylation during hypoxia could
potentially indirectly affect NO levels as well. To date, numerous hypoxamiRs were
shown to regulate Act activity indirectly. miR-21, miR-26, miR-221/222, and miR-486
bind to phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and, thus
activate Akt [89].
miR-21 is induced during hypoxia by HIF-1 and leads to Akt activation [90]. On the
other hand, miR-26 is reduced up on oxygen deprivation [91], having potential inhibi-
tory effect on Act activation during hypoxia. Interestingly, although miR-221/222 ex-
pression was not reported to be affected by hypoxia, miR221/222 overexpression in
Dicer-knockdown endothelial cells restored the elevated eNOS protein levels that was
induced by Dicer silencing [92].
Recent reports also provided evidence that miR-486 is upregulated during hypoxia and
contributes to VEGF signaling in bone marrow-derived mesynechymal stem cells [93].
HIF-1 drives Importantly, miR-155 that targets mRNA of Src homology-2 domain-
containing inositol 5 ∼ phosphatase 1 (SHIP1) as well [94]. SHIP1 is a PIP3 phosphatase
that deactivates Akt [94]. Hence, miR-155 impacts on NO levels during hypoxia may
result from both regulation of NOS3 expression and eNOS activity through Akt. It is
possible that miR-155 reduces NOS3 mRNA levels, but at the same time prevents loss
of NO via stimulating eNOS activity.
Furthermore, the phosphatidylinositol 3 kinase (PI3K) is the activator of the Akt
pathway and is targeted by miR-126 [95], the only miRNA considered to be specially
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served hypoxic downregulation of miR-126 contributes to increased VEGF expression
and Akt activation [97].
It has to be emphasized here that hypoxia interactions via increased Akt-mediated
serine phosphorylation during hypoxia disrupts hnRNP E1/NOS3 3′-UTR interactions,
allowing sONE- and miR-765-dependent destabilization of NOS3 mRNA [25]. Hence,
as best illustrated by miR-155, further studies are required to understand the interplay
between the negative effects of hypoxic Act activation on NOS3 levels and the positive
effect on eNOS activity.
During hypoxia, oxygen deprivation affects the levels ofthe soluble guanylyl cyclase
(sGC) that is the principal receptor for NO, and thus provides another level of regula-
tion of eNOS activity [98, 99]. Importantly, a recent study reported that hypoxia
reduces the sGC levels in mice and decreases NO-stimulated sGC activity [100]. The
same study that hypoxia induced murine miR-34a-5p to directly downregulate sGC
expression, and thus prevent NO signaling [100]. However, whether miR-34a-5p has a
similar impact on sGC in man requires further study.
Another interesting report identified an intronic “27-nt miRNA” derived from the
27-base pair repeats in intron 4 of NOS3 gene [101]. “27-nt miRNA” overexpres-
sion indirectly downregulated NOS3 mRNA and protein expression, and decreased
the NOS3 transcriptional efficiency [101]. However, this “27-nt miRNA” expression
was not confirmed in human cells nor the specific promoter sequence for this po-
tential miRNA was not identified. Hence, the further studies are required to evalu-
ate the biological function of this miRNA candidate.
The majority of the studies conducted so far have only considered simplified models
in which a single miRNA was analyzed in the context of one or more mRNA targets.
Although these studies advance our understanding of how miRNAs function as cellular
regulators, they neglect the fact that a single mRNA can be regulated by the simultan-
eous coordinated actions of a number of different miRNAs. For example, the NOS3 3′
UTR is 429 base long, the sONE 3′UTR is 1717 base long), whereas the miRNA seed
sequences are usually only 6-8 bases. Hence, NOS3/sONE RNAs can bind a combin-
ation of miRNAs simultaneously and these miRNAs will determine NOS3 mRNA’s
translation and stability. Furthermore, numerous reports conclude the biological role of
miRNAs based on correlation studies only or limit their experiments to observing the
effects of artificial miRNA overexpression. The latter approach ignores the importance
of physiological steady-state levels of miRNAs and theseoften result in the identification
of false positive targets.
Hypoxia provides an illustration of the bidirectional impact that miRNAs have on
endothelial NO homeostasis. The fact that the very same miRNA simultaneously
directly destabilizes NOS3 mRNA and stimulates eNOS activity emphasizes the import-
ance of maintaining the NO balance in both physiological and pathological conditions.
This illustrates the need to understand miRNA’s role in eNOS biology and particularly
with regard to the functional implications. Furthermore, the levels hypoxamiRs often
change dynamically during hypoxia [49, 50], and thus the temporal effects need to be
fully understood.
Interestingly, some hypoxamiRs like miR-155 are also modulated by oxidative
stress [102]. Hence, these miRNAs could provide an important sensor of eNOS
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requires further study.
It is also worthwhile to note that the endothelium from different vascular beds varies in
its molecular responses to hypoxia, including NOS3 and sONE mRNAs expression, as well
as the expression of the miRNAs. Also, the results are often conflicting regarding the
changes in miRNA levels during the hypoxia time course [50, 103]. Hence, we speculate
that endothelium-related miRNA expression in the different organs can be responsible for
the specific eNOS-dependent NO signaling in response to hypoxia/ischemia.
Concluding remarks
It is clear that understanding the cellular pathways that regulate NO bioavailability in
human endothelium under hypoxia is necessary in order to develop novel treatments
for cardiovascular disorders. The endothelial NOS3 expression and NO bioavailability
during hypoxia results from a complicated equilibrium that exist between the proapop-
totic and survival pathways as summarized in Fig. 3. Although the molecular mecha-
nisms of the cellular response to hypoxia and ER stress have been extensively studied,
there is limited information regarding their interplay and the role of miRNAs in these
processes. Furthermore, a large number of both transcriptional and posttranscriptional
factors that maintain endothelial NO homeostasis [104] can also be involved in the
miRNAs regulatory networks.
Considering the recent interest in the development of novel micro-RNA-based
therapies for human pathologies, it is tempting to speculate that miRNAs or their analogs
offer a novel therapeutic approach in regulating endothelial NO bioavailability. Although
we can modulate the cellular miRNA levels (either with their analogs (miRNAFig. 3 The transcriptional and posttranscriptional influence of hypoxia on NOS3 mRNA levels. During
hypoxia, HIF-1 and HIF-2 accumulate in the nucleus, where they bind to a sequence in the promoter region
of NOS3 termed the hypoxia-response element (HRE), and in doing so, induce NOS3 expression. Hypoxia
disrupts hnRNP E1/NOS3 3′-UTR interactions and makes this transcript susceptible to sONE and miRNA-
related down-regulation. HIF-1 induces miR-155 that along with miR-765 and miR-24 destabilizes NOS3
mRNA. Furthermore, during hypoxia, miR-214 has negative effect on NOS3 expression. Hypoxia is
accompanied by deregulation of ER homeostasis and HIF-1-related activation of the ER stress response. The
proadaptive and proangiogenic ER stress transcription factor sXBP1 stimulates NOS3 expression transcriptionally
and postranscriptionally through reduction of miR-24, miR-125 and miR-214. However, another proapoptotic ER
stress transcription factor, CHOP, binds to the 5′UTR and represses transcription. The hypoxamiRs also modulate
Act signaling pathway and consequently eNOS activity. During hypoxia, the changes in the expression levels of
miR-155, miR-101, miR-486, miR-21 and miR-126 stimulate Akt activation, whereas miR-26 prevents Act
signaling. The (+) expression profile changed during hypoxia contributes to increased expression and
activity of NOS3; the (-) expression profile changed during hypoxia has a negative effect on the expression and
activity of NOS3; (¥) depicts indirect effects on the NOS3 gene
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main a main limitation of such strategies. Since a single miRNA can regulate hundreds of
different mRNAs, an alteration in this miRNA expression pattern will have a wide range
of consequences for cell metabolism. miR-155 provides a perfect example how wide and
complex potential influence of single miRNA is on eNOS activity. Understanding the
miRNA governed balance between decreasing NOS3 expression and increasing eNOS
activity is crucial for the development of further therapeutic approaches.
Fortunately, a novel alternative approach relies on target protectors that add specifi-
city to the mRNA of interest. Target protectors are single-stranded, modified RNAs
that inhibit the interaction of the miRNA with a specific target without blocking the
effects of the particular miRNA on other targets [105]. Hence, target protectors might
appear to be extremely helpful tools in sorting out complex role of miRNA in maintaining
NO homeostasis. And finally, one has to be aware of the cell- and tissue-specific differ-
ences in miRNA expression during hypoxia. Despite these concerns, understanding the
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